These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16999914)

  • 1. [Taxanes in metastatic breast cancer. An analysis of a systematic Cochrane review].
    Nielsen DL; Kamby C
    Ugeskr Laeger; 2006 Sep; 168(37):3117-20. PubMed ID: 16999914
    [No Abstract]   [Full Text] [Related]  

  • 2. [Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab].
    Bria E; Vanni B; Cuppone F; Calabretta F; Campanella C; Torsello A; Terzoli E
    Suppl Tumori; 2004; 3(4):S65-6. PubMed ID: 15206216
    [No Abstract]   [Full Text] [Related]  

  • 3. [Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab. What repercussions will they have in clinical practice?].
    Colozza M
    Suppl Tumori; 2004; 3(4):S67-9. PubMed ID: 15206217
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
    Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling the mystery of the TACT trial.
    Martin M
    Lancet; 2009 May; 373(9676):1662-3. PubMed ID: 19447241
    [No Abstract]   [Full Text] [Related]  

  • 6. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer.
    Nowak AK; Wilcken NR; Stockler MR; Hamilton A; Ghersi D
    Lancet Oncol; 2004 Jun; 5(6):372-80. PubMed ID: 15172358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
    Dang C; Hudis C
    Clin Breast Cancer; 2006 Apr; 7(1):51-8. PubMed ID: 16764744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Taxanes as adjuvants in breast cancer. What repercussions will this have in clinical practice?].
    Mosconi AM; Montedoro M
    Suppl Tumori; 2004; 3(4):S18-20. PubMed ID: 15206203
    [No Abstract]   [Full Text] [Related]  

  • 9. [Role of taxanes in treatment of breast cancer].
    Gorbunova VA; Besova NS
    Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
    [No Abstract]   [Full Text] [Related]  

  • 10. [Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"].
    Ejlertsen B; Mouridsen H
    Ugeskr Laeger; 2004 Jun; 166(25):2434-6. PubMed ID: 15283108
    [No Abstract]   [Full Text] [Related]  

  • 11. Taxanes in breast cancer: an update.
    Conlin AK; Seidman AD
    Curr Oncol Rep; 2007 Jan; 9(1):22-30. PubMed ID: 17164044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Wilcken N; Simes RJ
    Br J Cancer; 2005 Aug; 93(3):293-301. PubMed ID: 16052223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel for treatment of solid tumours: a systematic review of clinical data.
    Montero A; Fossella F; Hortobagyi G; Valero V
    Lancet Oncol; 2005 Apr; 6(4):229-39. PubMed ID: 15811618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?
    Crown J
    Lancet; 2003 Aug; 362(9385):677-8. PubMed ID: 12957087
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
    Cuppone F; Bria E; Carlini P; Milella M; Felici A; Sperduti I; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
    Cancer; 2008 Jul; 113(2):238-46. PubMed ID: 18470908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. If there is no overall survival benefit in metastatic breast cancer: does it imply lack of efficacy? Taxanes as an example.
    Vriens BE; Lobbezoo DJ; de Hoon JP; Veeck J; Voogd AC; Tjan-Heijnen VC
    Cancer Treat Rev; 2013 Apr; 39(2):189-98. PubMed ID: 22658318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adjuvant chemotherapy for breast cancer and targeted therapies].
    Dufresne A; Bachelot T; Blay JY
    Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.